Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
29 avr. 2021 02h00 HE
|
Verona Pharma plc
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and...
Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease
27 avr. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
23 avr. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
21 avr. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Lisa Deschamps Joins Verona Pharma as Non-Executive Director
02 mars 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
01 mars 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
25 févr. 2021 02h00 HE
|
Verona Pharma plc
Positive Phase 2 results with pMDI ensifentrine in COPD Enrollment ongoing in ENHANCE Phase 3 program Up to $30 million debt finance facility increases financial flexibility Conference...
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
18 févr. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
02 févr. 2021 06h17 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit...
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
02 févr. 2021 02h00 HE
|
Verona Pharma plc
Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”),...